- Home
- SIBN vs MGTX Comparison
SIBN vs MGTX Comparison
Compare SIBN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- MGTX
- Stock Information
- Founded
- SIBN 2008
- MGTX 2015
- Country
- SIBN United States
- MGTX United States
- Employees
- SIBN N/A
- MGTX N/A
- Industry
- SIBN Medical/Dental Instruments
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIBN Health Care
- MGTX Health Care
- Exchange
- SIBN Nasdaq
- MGTX Nasdaq
- Market Cap
- SIBN 547.3M
- MGTX 570.5M
- IPO Year
- SIBN 2018
- MGTX N/A
- Fundamental
- Price
- SIBN $14.04
- MGTX $7.33
- Analyst Decision
- SIBN Strong Buy
- MGTX Strong Buy
- Analyst Count
- SIBN 6
- MGTX 2
- Target Price
- SIBN $24.50
- MGTX $24.50
- AVG Volume (30 Days)
- SIBN 370.2K
- MGTX 770.2K
- Earning Date
- SIBN 05-05-2025
- MGTX 03-13-2025
- Dividend Yield
- SIBN N/A
- MGTX N/A
- EPS Growth
- SIBN N/A
- MGTX N/A
- EPS
- SIBN N/A
- MGTX N/A
- Revenue
- SIBN $167,178,000.00
- MGTX $33,279,000.00
- Revenue This Year
- SIBN $18.52
- MGTX $512.49
- Revenue Next Year
- SIBN $16.36
- MGTX $2.91
- P/E Ratio
- SIBN N/A
- MGTX N/A
- Revenue Growth
- SIBN 20.37
- MGTX 137.42
- 52 Week Low
- SIBN $11.70
- MGTX $3.85
- 52 Week High
- SIBN $19.16
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- SIBN 33.41
- MGTX 52.33
- Support Level
- SIBN $13.80
- MGTX $7.13
- Resistance Level
- SIBN $15.40
- MGTX $7.95
- Average True Range (ATR)
- SIBN 0.58
- MGTX 0.50
- MACD
- SIBN -0.12
- MGTX -0.02
- Stochastic Oscillator
- SIBN 12.90
- MGTX 52.35
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.